These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25802911)

  • 1. Sodium phenylbutyrate coated granules (Pheburane). Defective urea synthesis: a welcome formulation.
    Prescrire Int; 2015 Feb; 24(157):35-6. PubMed ID: 25802911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Follow-Up on a Cohort Temporary Utilization Authorization (ATU) Survey of Patients Treated with Pheburane (Sodium Phenylbutyrate) Taste-Masked Granules.
    Kibleur Y; Guffon N
    Paediatr Drugs; 2016 Apr; 18(2):139-44. PubMed ID: 26747635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a Nationwide Cohort Temporary Utilization Authorization (ATU) survey of patients in france treated with Pheburane(®) (Sodium Phenylbutyrate) taste-masked granules.
    Kibleur Y; Dobbelaere D; Barth M; Brassier A; Guffon N
    Paediatr Drugs; 2014 Oct; 16(5):407-15. PubMed ID: 24962711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycerol phenylbutyrate (Ravicti) for urea cycle disorders.
    Med Lett Drugs Ther; 2014 Aug; 56(1449):77-8. PubMed ID: 25118801
    [No Abstract]   [Full Text] [Related]  

  • 5. Developing a new formulation of sodium phenylbutyrate.
    Guffon N; Kibleur Y; Copalu W; Tissen C; Breitkreutz J
    Arch Dis Child; 2012 Dec; 97(12):1081-5. PubMed ID: 22941860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disorders.
    Monteleone JP; Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Berry SA; Lemons C; Dickinson K; Coakley D; Lee B; Scharschmidt BF
    J Clin Pharmacol; 2013 Jul; 53(7):699-710. PubMed ID: 23775211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders.
    Cederbaum SD; Edwards J; Kellmeyer T; Peters Y; Steiner RD
    Mol Genet Metab; 2023 Apr; 138(4):107558. PubMed ID: 37004302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.
    Berry SA; Lichter-Konecki U; Diaz GA; McCandless SE; Rhead W; Smith W; Lemons C; Nagamani SC; Coakley DF; Mokhtarani M; Scharschmidt BF; Lee B
    Mol Genet Metab; 2014 May; 112(1):17-24. PubMed ID: 24630270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
    Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Bart S; Kronn D; Zori R; Cederbaum S; Dorrani N; Merritt JL; Sreenath-Nagamani S; Summar M; Lemons C; Dickinson K; Coakley DF; Moors TL; Lee B; Scharschmidt BF
    Mol Genet Metab; 2012 Nov; 107(3):308-14. PubMed ID: 22958974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.
    Nagamani SC; Diaz GA; Rhead W; Berry SA; Le Mons C; Lichter-Konecki U; Bartley J; Feigenbaum A; Schulze A; Longo N; Berquist W; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Kronn D; Zori R; Cederbaum S; Merritt JL; Wong D; Coakley DF; Scharschmidt BF; Dickinson K; Marino M; Lee BH; Mokhtarani M
    Mol Genet Metab; 2015; 116(1-2):29-34. PubMed ID: 26296711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
    Smith W; Diaz GA; Lichter-Konecki U; Berry SA; Harding CO; McCandless SE; LeMons C; Mauney J; Dickinson K; Coakley DF; Moors T; Mokhtarani M; Scharschmidt BF; Lee B
    J Pediatr; 2013 Jun; 162(6):1228-34, 1234.e1. PubMed ID: 23324524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial to examine the impact of food on pharmacokinetics of 4-phenylbutyrate and change in amino acid availability after a single oral administration of sodium 4-phenylbutyrarte in healthy volunteers.
    Osaka S; Nakano S; Mizuno T; Hiraoka Y; Minowa K; Hirai S; Mizutani A; Sabu Y; Miura Y; Shimizu T; Kusuhara H; Suzuki M; Hayashi H
    Mol Genet Metab; 2021 Apr; 132(4):220-226. PubMed ID: 33648834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders.
    Burrage LC; Jain M; Gandolfo L; Lee BH; ; Nagamani SC
    Mol Genet Metab; 2014; 113(1-2):131-5. PubMed ID: 25042691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders.
    Berry SA; Vockley J; Vinks AA; Dong M; Diaz GA; McCandless SE; Smith WE; Harding CO; Zori R; Ficicioglu C; Lichter-Konecki U; Perdok R; Robinson B; Holt RJ; Longo N
    Mol Genet Metab; 2018 Nov; 125(3):251-257. PubMed ID: 30217721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation and Clinical Evaluation of Sodium Benzoate Oral Solution for the Treatment of Urea Cycle Disorders in Pediatric Patients.
    Maines E; Urru SAM; Burri E; Piccoli G; Pedrolli A; Pasqualini A; Burlina AL; Temporin G
    AAPS PharmSciTech; 2020 Mar; 21(3):100. PubMed ID: 32152836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urea cycle disorder drug approved.
    Guha M
    Nat Biotechnol; 2013 Apr; 31(4):274. PubMed ID: 23563410
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized trial to study the comparative efficacy of phenylbutyrate and benzoate on nitrogen excretion and ureagenesis in healthy volunteers.
    Nagamani SCS; Agarwal U; Tam A; Azamian M; McMeans A; Didelija IC; Mohammad MA; Marini JC
    Genet Med; 2018 Jul; 20(7):708-716. PubMed ID: 29693650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Averting the foul taste of pediatric medicines improves adherence and can be lifesaving - Pheburane
    Koren G; Rieder MJ; Amitai Y
    Patient Prefer Adherence; 2016; 10():2141-2144. PubMed ID: 27799750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.
    McGuire BM; Zupanets IA; Lowe ME; Xiao X; Syplyviy VA; Monteleone J; Gargosky S; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt BF
    Hepatology; 2010 Jun; 51(6):2077-85. PubMed ID: 20512995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
    Lee B; Rhead W; Diaz GA; Scharschmidt BF; Mian A; Shchelochkov O; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Gargosky S; Mokhtarani M; Berry SA
    Mol Genet Metab; 2010 Jul; 100(3):221-8. PubMed ID: 20382058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.